Preoperative Optimization of the Hernia Patient


Introduction

  • Patients presenting for elective hernia repair often possess risk factors for wound morbidity and hernia recurrence that the surgeon cannot mend. Defect size, age, multiplicity of recurrences, and the presence of an ostomy or infected prosthetic are intrinsic variables for which little can be done between the preoperative assessment and operative date. However, certain risk factors are malleable and warrant close investigation in the preoperative period. This chapter highlights areas where optimization is realistic and can be pivotal in reducing postoperative wound morbidity and hernia recurrence. These principles allow for optimization of the most complex patients and ideally prevent “routine” cases from becoming complex.

Smoking Cessation

Level of Evidence—IA

  • See studies by and .

Data for Patient Counseling

  • Smokers are twice as likely to develop a hernia recurrence after repair (odds ratio [OR] 2.07; 95% confidence interval [CI], 1.23–3.47).

  • Smokers are more than twice as likely to develop a wound complication (OR 2.27; 95% CI, 1.82–2.84).

  • Wound infection rates are higher in smokers (OR 1.79; 95% CI, 1.57–2.04).

Appropriate Intervention

  • Smoking cessation for a minimum of 4 weeks before hernia repair is recommended.

  • Randomized trials of short-term cessation (≤3 weeks) have not shown efficacy.

  • Nicotine replacement therapy is acceptable.

Monitoring

  • A serum cotinine level will not be affected by nicotine replacement therapy.

  • A serum cotinine level is able to confirm 2 weeks of abstinence.

Our Approach

  • Extensive patient counseling is offered.

  • If a disingenuous report of cigarette abstinence is suspected, a serum cotinine level is obtained during preadmission testing.

  • A patient’s failure to quit smoking by the second clinic visit delays the operation by 6 months.

  • A second failure results in the patient being released from the practice.

Comment

  • Electronic cigarettes (“e-cigarettes”) have not been regulated by the U.S. Food and Drug Administration, and their safety is unknown. Studies have demonstrated the presence of the same toxic compounds found in cigarettes in varying concentrations that are not reported to the consumer. The Food and Drug Administration is currently attempting to expand its authority to regulate such products. In the meantime, we do not allow patients to use e-cigarettes.

Diabetes Management

Level of Evidence—IIb-B

  • See studies by , , , and .

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here